Filamin A in triple negative breast cancer

被引:1
|
作者
Giovannelli, Pia [1 ]
Di Donato, Marzia [1 ]
Licitra, Fabrizio [1 ]
Sabbatino, Emilia [1 ]
Tutino, Viviana [1 ]
Castoria, Gabriella [1 ]
Migliaccio, Antimo [1 ]
机构
[1] Univ Campania L Vanvitelli, Dept Precis Med, Via L De Crecchio 7, I-80138 Naples, Italy
关键词
Triple negative breast cancer; Filamin A; TNBC marker; Androgen receptor; ACTIN-BINDING PROTEIN; PERIVENTRICULAR HETEROTOPIA; ANDROGEN RECEPTOR; CROSS-LINKING; EXPRESSION; INVASION; SURVIVAL; FLNA; PHOSPHORYLATION; MIGRATION;
D O I
10.1016/j.steroids.2024.109380
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Triple-negative breast cancer is a rare but highly heterogeneous breast cancer subtype with a limited choice of specific treatments. Chemotherapy remains the only efficient treatment, but its side effects and the development of resistance consolidate the urgent need to discover new targets. In TNBC, filamin A expression correlates to grade and TNM stage. Accordingly, this protein could constitute a new target for this BC subtype. Even if most of the data indicates its direct involvement in cancer progression, some contrasting results underline the need to deepen the studies. To elucidate a possible function of this protein as a TNBC marker, we summarized the main characteristic of filamin A and its involvement in physiological and pathological processes such as cancer. Lastly, we scrutinized its actions in triple-negative breast cancer and highlighted the need to increase the number of studies useful to better clarify the role of this versatile protein as a marker and target in TNBC, alone or in "collaboration" with other proteins with a relevant role in this BC subgroup.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Triple-negative breast cancer
    Chacon, Reinaldo D.
    Costanzo, Maria V.
    BREAST CANCER RESEARCH, 2010, 12
  • [22] Characterization of Triple Negative Breast Cancer
    Heredia Martinez, Bernardo Enrique
    Gonzalez Fernandez, Hailyn
    FINLAY, 2020, 10 (03): : 259 - 268
  • [23] Patients with triple negative breast cancer
    Di Leo, A.
    Oakman, C.
    Moretti, E.
    Galardi, F.
    Biagioni, C.
    Santarpia, L.
    BREAST, 2011, 20 : S13 - S14
  • [24] Therapies for triple negative breast cancer
    Andreopoulou, Eleni
    Schweber, Sarah J.
    Sparano, Joseph A.
    McDaid, Hayley M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (07) : 983 - 998
  • [25] The management of triple negative breast cancer
    Harbeck, N.
    BREAST, 2014, 23 : S5 - S5
  • [26] Triple-negative breast cancer
    Bartsch R.
    Ziebermayr R.
    Zielinski C.C.
    Steger G.G.
    Wiener Medizinische Wochenschrift, 2010, 160 (7-8) : 174 - 181
  • [27] Triple-Negative Breast Cancer
    Liedtke, Cornelia
    Schmutzler, Rita
    Schneeweiss, Andreas
    Loibl, Sybille
    Thill, Marc
    Heitz, Florian
    BREAST CARE, 2010, 5 (05) : 359 - 363
  • [28] Triple-negative breast cancer
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2020, 120 (08) : 22 - 23
  • [29] Triple-negative breast cancer
    Reinaldo D Chacón
    María V Costanzo
    Breast Cancer Research, 12
  • [30] Octogenarians with triple negative breast cancer
    Spoer, Daisy L.
    Ghyasi, Niloofar
    Thorson, Teagan L.
    Huffman, Samuel S.
    Berger, Lauren E.
    Lava, Christian X.
    Lin, Chung -Fu
    Masanam, Monika K.
    Rosal, Lindy M.
    Boisvert, Marc E.
    Wehner, Patricia B.
    Greenwalt, Ian T.
    Son, Jennifer D.
    Convit, Rafael J.
    Tousimis, Eleni
    Song, David H.
    Fan, Kenneth L.
    Cruz, Lucy M. De La
    ANNALS OF BREAST SURGERY, 2024, 8